Representative Angie Craig Urges CMS Administrator to Rescind Price Increase for Medicare Part B Premiums
Last year, CMS announced a 14.5% increase in premiums for 2022 – an increase largely driven by the exorbitant launch price of a newly approved Alzheimer’s drug
WASHINGTON, D.C. — Today, U.S. Representative Angie Craig urged the Centers for Medicare and Medicaid Services to revisit and reverse a significant hike in premiums, which she argued was exacerbating financial hardships experienced by millions of older Americans. In a letter to CMS Administrator Chiquita Brooks-LaSure, Craig called on the agency to reconsider a 14.5% increase in Medicare Part B premiums in 2022 – which represents the single largest dollar increase in the health insurance program's history.
Late last year, CMS announced that Medicare's Part B monthly premium for 2022 would increase by $21.60 – an increase largely driven by the exorbitant launch price of a newly approved Alzheimer's drug called Aduhlem. In her letter, Craig reminded Brooks-LaSure of the Biden Administration's promise to lower health care costs – especially for the nation's seniors – and urged further action to reduce costs for the American people.
"Millions of older Americans, many of whom rely on fixed incomes and limited savings to cover costs, are already struggling to make ends meet. Especially in these extraordinary times, my constituents cannot bear additional and unnecessary financial burdens related to their monthly health care premiums," wrote Representative Craig. "Before entering office, President Biden made a commitment to the American people that he would use all levers of government to expand access and lower the cost of health care – especially for older Americans. This is your opportunity to make good on that promise and provide relief to millions of Americans who need it most."
Medicare officials announced that the unprecedented price increase – the largest dollar increase in the health insurance program's history – was due, in part, to the high price of Aduhlem. However, earlier this year, Health and Human Services Secretary Xavier Becerra called on CMS to reevaluate the increase, citing a recent price reduction of Aduhlem from $56,000 to about $28,000. Craig and her colleagues in Congress had previously urged CMS to honor Secretary Becerra's request, arguing that the historic premium increases could prove unaffordable to the nation's seniors – especially amidst a deadly global pandemic that has already increased prices for Americans in a broad array of sectors.
You can find the full text of the letter
April 22, 2022
The Honorable Chiquita Brooks-LaSure
Administrator
The Centers for Medicare & Medicaid Services
U.S. Department of Health and Human Services 7500 Security Boulevard
Baltimore, MD 21244
Dear Administrator Brooks-LaSure:
Thank you for the work you do on behalf of the millions of Americans who rely on Medicare for their health care coverage. Earlier this year, I led 37 of my colleagues in a letter urging the Centers for Medicare & Medicaid Services (CMS) to reevaluate Medicare Part B's 2022 premium increase. As CMS continues to reassess this rate increase, I write again today to reaffirm my support for reversing the increase and ensuring our seniors do not pay a dollar more than what is necessary.
As you know, Medicare Part B premiums increased in 2022 by a record 14.5%. One of the driving factors was the Food and Drug Administration's approval of the high-priced Alzheimer's treatment, Aduhelm, whose list price was initially $56,000 a year. At the time, it was uncertain the extent to which the drug would be covered under Medicare, but it was clear it would be costly. A Kaiser Family Foundation analysis estimated that Medicare spending could increase by $30 billion annually if only 500,000 patients used the drug. Given the high list price and the coverage uncertainty, CMS needed to raise Part B premiums from $148.50 to $170.10 to protect the program's solvency.
Since then, Aduhelm's manufacturer, Biogen, lowered the list price from $56,000 to $28,200 per year – a 50% decrease. CMS recently issued its final coverage determination for Aduhelm, which limits coverage to beneficiaries enrolled in clinical trials. Taken together, these developments mean that Aduhelm will not pose the cost burden on the system that CMS originally projected. In response, Secretary Becerra indicated that CMS would continue to reevaluate the increase and a final determination would be forthcoming.
Millions of older Americans, many of whom rely on fixed incomes and limited savings to cover costs, are already struggling to make ends meet. Especially in these extraordinary times, my constituents cannot bear additional and unnecessary financial burdens related to their monthly health care premiums. Before entering office, President Biden made a commitment to the American people that he would use all levers of government to expand access and lower the cost of health care – especially for older Americans. This is an opportunity to make good on that promise and provide relief to millions of Americans who need it most.
I recognize the unprecedented nature of the request, but believe it is justified given the unique circumstances. Now that a major reason for the premium increase has been reversed, I urge swift action to provide my constituents on Medicare with relief. Thank you for very much for your consideration.
###